Regulatory Strategic Planning Flashcards

When developing a regulatory strategy for a combination product in the US, which FDA center typically takes lead jurisdiction?

Answer: The center with the most expertise in the primary mode of action

FDA assigns lead jurisdiction to the center whose regulation is most appropriate based on the primary mode of action of the combination product.

A company is planning global market entry for a Class II medical device. Which regulatory pathway typically offers the fastest US market access?

Answer: 510(k) with predicate

A 510(k) submission demonstrating substantial equivalence to a legally marketed predicate device is the fastest pathway for Class II devices.

In regulatory strategic planning, a 'critical path' analysis primarily helps identify:

Answer: Activities that directly impact the overall project timeline

Critical path analysis identifies the sequence of dependent activities that determine the minimum time required to complete a project.

Which of the following best describes a 'regulatory gap analysis' in strategic planning?

Answer: Assessing current dossier status against requirements for target markets

A regulatory gap analysis compares the existing data package against the submission requirements for target regulatory agencies to identify what additional work is needed.

Under ICH E8(R1), which approach is emphasized for clinical trial design in regulatory strategy?

Answer: Risk-based and fit-for-purpose design tailored to the specific question

ICH E8(R1) emphasizes a risk-proportionate, fit-for-purpose approach to clinical study design that focuses on quality factors critical to the study's objectives.

A regulatory affairs professional is assessing whether to use FDA's Breakthrough Therapy Designation (BTD). Which criterion is most critical?

Answer: Preliminary clinical evidence shows substantial improvement over available therapy for serious conditions

BTD requires preliminary clinical evidence indicating that the drug may demonstrate substantial improvement over existing therapies on a clinically significant endpoint for serious conditions.

In the context of regulatory strategic planning, 'lifecycle management' refers to:

Answer: Planning regulatory activities from development through post-market to maximize product value

Regulatory lifecycle management encompasses all regulatory activities from initial development through post-approval changes, line extensions, and eventual product discontinuation.